Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLB | Q8NCG7 | 2/20 | 0.44 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.39 |
| ▸ | FLT1 | P17948 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7719578 | 0.88 | RAB9A (0.40) | HDAC2HDAC8HDAC6EPHX2NAMPT | |
| SCHEMBL7723034 | 0.86 | DAGLB (0.46) | DAGLBDAGLATRPV1FLT1KDR | |
| SCHEMBL7722987 | 0.86 | NAMPT (0.45) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL7724742 | 0.84 | EPHX2 (0.46) | EPHX2 | |
| SCHEMBL7722998 | 0.83 | NAMPT (0.46) | NAMPT | |
| SCHEMBL7723044 | 0.80 | EPHX2 (0.46) | EPHX2 | |
| Fumaric Acid SCHEMBL7723100 | 0.80 | TAAR1 (0.48) | EPHX2NAMPT | |
| Fumaric Acid SCHEMBL7723104 | 0.80 | TAAR1 (0.48) | EPHX2NAMPT | |
| SCHEMBL7723864 | 0.79 | RAB9A (0.51) | HDAC2HDAC8HDAC6NAMPT | |
| SCHEMBL7723935 | 0.77 | ALDH1A1 (0.39) | EPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420398-B2 | FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-11-15 | — | — | US | disclosed |
| EP-1103543-A1 | NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | TNF, UACA, HRH4 | DAGLB 4340/4885DAGLA 3729/4885TRPV1 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.